-+ 0.00%
-+ 0.00%
-+ 0.00%

Xtant Medical Raises FY2026 Sales Guidance from $95.000M-$99.000M to $101.000M-$105.000M vs $96.725M Est

Benzinga·05/13/2026 11:02:05
Listen to the news

2026 Financial Guidance

The Company is today increasing its full-year 2026 revenue guidance to a range of $101 million to $105 million, from $95 million to $99 million previously, to reflect the recently announced exclusive license agreement with Dilon Technologies and anticipated incremental revenue contribution from Dilon's HEMOBLAST® Bellows.